NO984851L - DHEA kombinasjonsterapi - Google Patents

DHEA kombinasjonsterapi

Info

Publication number
NO984851L
NO984851L NO984851A NO984851A NO984851L NO 984851 L NO984851 L NO 984851L NO 984851 A NO984851 A NO 984851A NO 984851 A NO984851 A NO 984851A NO 984851 L NO984851 L NO 984851L
Authority
NO
Norway
Prior art keywords
interleukin
compounds
compound
antiserum
combinations
Prior art date
Application number
NO984851A
Other languages
English (en)
Other versions
NO984851D0 (no
Inventor
Patrick T Prendergast
Original Assignee
Patrick T Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick T Prendergast filed Critical Patrick T Prendergast
Publication of NO984851D0 publication Critical patent/NO984851D0/no
Publication of NO984851L publication Critical patent/NO984851L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Det er tilveiebrakt medikamenter, fremgangsmåter for fremstilling av disse og sett som innbefatter (1) en 17-ketosteroidforbindelse og/eller (2) antiserum enten poly- eller monoklonalt med interleukin 10, interleukin 2 eller interleukin 12, eller med en hvilke som helst forbindelse som effektivt kan inhibere syntesen av den biologiske funksjonen til interleukin 10, interleukin 12 eller interleukin 2, eller med et interleukin 10, interleukin 12 eller interleukin 2 reseptormolekyl blokkerende middel, eller med antiserum, enten polyklonalt eller monoklonalt for human a-fetoprotein. Det er også tilveiebrakt fremgangsmåte for behandling som omfatter slike forbindelser eller kombinasjoner av forbindelser, inkludert forsterkning av Th, immunbeskyttende respons ved anvendelse av 17-ketosteroidforbindelse som et anti-viralt, anti-bakterielt, anti-mykoplasma eller anti-intracellulært parasitisk middel og andre behandlinger for forskjellige forbindelser og kombinasjoner som beskrevet.
NO984851A 1996-04-17 1998-10-16 DHEA kombinasjonsterapi NO984851L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1569596P 1996-04-17 1996-04-17
PCT/IB1997/000414 WO1997038695A1 (en) 1996-04-17 1997-04-17 Dhea combination therapy

Publications (2)

Publication Number Publication Date
NO984851D0 NO984851D0 (no) 1998-10-16
NO984851L true NO984851L (no) 1998-12-17

Family

ID=21773003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984851A NO984851L (no) 1996-04-17 1998-10-16 DHEA kombinasjonsterapi

Country Status (9)

Country Link
EP (1) EP0901375A1 (no)
JP (1) JP2000508654A (no)
KR (1) KR20000005539A (no)
CN (1) CN1216470A (no)
AU (1) AU734807B2 (no)
CA (1) CA2251733A1 (no)
IL (1) IL126623A0 (no)
NO (1) NO984851L (no)
WO (1) WO1997038695A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
JP2002531407A (ja) * 1998-11-24 2002-09-24 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド マラリアの治療並びにアフリカトリパノソーマ感染症及びアメリカトリパノソーマ感染症の治療における１７−ケトステロイド化合物及びその誘導体、代謝物及び前駆体の使用
NZ511721A (en) * 1998-11-24 2004-07-30 Hollis Eden Pharmaceuticals Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
AU1923500A (en) * 1998-11-27 2000-06-19 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis
EP2983705A2 (en) * 2013-04-10 2016-02-17 Skau Aps Use of immune suppressive peptides as adjuvants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
HU220103B (hu) * 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
CA2251733A1 (en) 1997-10-23
NO984851D0 (no) 1998-10-16
EP0901375A1 (en) 1999-03-17
WO1997038695A1 (en) 1997-10-23
AU2574197A (en) 1997-11-07
KR20000005539A (ko) 2000-01-25
AU734807B2 (en) 2001-06-21
JP2000508654A (ja) 2000-07-11
IL126623A0 (en) 1999-08-17
CN1216470A (zh) 1999-05-12

Similar Documents

Publication Publication Date Title
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
BR0013201A (pt) Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado
IL158088A (en) Use of an antibody linked to ailim for the preparation of a pharmacological preparation for suppressing or preventing inflammatory bowel disease
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
CA2132953A1 (en) Monospecific polyclonal antibodies to shiga-like toxins
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
DK0664708T3 (da) Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe
Rivera et al. Prophylaxis and treatment with a monoclonal antibody of tetrodotoxin poisoning in mice
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
NO870476D0 (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
NO984851L (no) DHEA kombinasjonsterapi
DE69324579T2 (de) Gentechnologisch hergestellte antikörper
DE69610106D1 (de) Toxine und toxoide von clostridium difficile als schleimhautadjuvans
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
KR890700133A (ko) 인체단일클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료제
PT90296A (pt) Processo para a preparacao de anticorpos monoclonais contra pseudomonas aeruginosa e de composicoes farmaceuticas que os contem
MX9202912A (es) Nuevos anticuerpos monoclonales dirigidos contra el virus de la inmunosuficiencia humana y proceso para su preparacion.
EP0450573A3 (en) Antibodies for the treatment and diagnosis of pseudomonas aeruginosa infections
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application